Sean Saint

I think I've done enough.

You certainly ask interesting questions.

Ooh, yeah, long and winding road, actually.

Matt, I got involved in diabetes, gosh, over 20 years ago now with a little company you may have heard of called Dexcom.

Obviously, they're not a little company anymore, but at the time, they really were.

We didn't have real-time continuous glucose monitoring at that stage, and looking back on it 22 years later, we had no idea what it was ultimately going to become.

But yeah, I spent about five years there.

Later moved on to tandem diabetes care, designing insulin pumps.

And it was oddly a tandem that I got diagnosed with type 1 diabetes myself.

I'd been in the industry almost a decade at that stage.

And to have that happen to me as the director of advanced technologies at an insulin pump company was pretty ironic.

But, you know, it did set me up for, you know, my future beyond that.

At that point, I would say there's two things that happened.

The first is that I met our founder from Beta Bionics, Ed Damiano, at ADA.

And I walked up to him afterwards.

I'd heard him talk about this crazy idea of bi-hormonal insulin delivery, insulin and glucagon delivery.

And, yeah.

I was just amazed and I asked him how I could help.

And that started our collaboration back in 2010.

And then a few years later, I left Tandem to go found Companion Medical, which was the opposite way of doing the same thing, which was we wanted to make a smart pen, a smart insulin pen, which was just another way of bringing better technologies to more people.